ParkinsonFranceV1, PubMed, Checkpoint, bibRecord, 001521

Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Identifieur interne : 001521 ( PubMed/Checkpoint ); précédent : 001520; suivant : 001522

Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Auteurs : A. Delacourte [France]

Source :

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [ 0753-3322 ] ; 1994.

RBID : pubmed:7858159

English descriptors

KwdEn :
- Alzheimer Disease (diagnosis), Alzheimer Disease (metabolism), Biomarkers, Dementia (complications), Dementia (metabolism), Down Syndrome (metabolism), Humans, Nerve Degeneration, Neurofibrillary Tangles (chemistry), Neurofibrillary Tangles (pathology), Parkinson Disease (complications), tau Proteins (chemistry), tau Proteins (metabolism).
MESH :
- chemical , chemistry : tau Proteins.
- chemical , metabolism : tau Proteins.
- chemical : Biomarkers.
- chemistry : Neurofibrillary Tangles.
- complications : Dementia, Parkinson Disease.
- diagnosis : Alzheimer Disease.
- metabolism : Alzheimer Disease, Dementia, Down Syndrome.
- pathology : Neurofibrillary Tangles.
- Humans, Nerve Degeneration.

Abstract

Paired Helical Filaments (PHF) accumulate in the degenerating neurons from the associative cortical brain areas during Alzheimer's disease. They are composed of a triplet of hyperphosphorylated microtubule-associated protein Tau, called Tau 55, 64, 69 or PHF-Tau. The distribution of PHF-Tau in the different brain areas corroborates neuropathological observations and specifies that: the entorhinal cortex and hippocampus are vulnerable regions specifically affected by Alzheimer-type neurofibrillary degeneration during aging, the temporal cortex is already affected at the very first stage of clinical manifestations, almost the whole brain is concerned by neurofibrillary degeneration at the end-stages of the disease. Tau-PHF are also observed in the cortical areas from Parkinson patients with dementia, and more especially in the prefrontal cortex. Tau pathology for Progressive Supranuclear Palsy is significantly different, with a doublet of pathological Tau, namely Tau 64 and 69, in almost all cortical and subcortical areas. Therefore, the presence of pathological Tau proteins in several associative cortical areas is always associated with severe intellectual impairment. Finally, PHF-Tau are powerful biochemical markers of the degenerating process which could be used for setting up an early biological diagnosis test of Alzheimer's disease based upon the immunodetection of PHF antigens in the CSF, as well as for developing experimental models of neurodegeneration.

PubMed: 7858159

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001691
to stream PubMed, to step Curation: 001650

Links to Exploration step

pubmed:7858159

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.</title>
<author><name sortKey="Delacourte, A" sort="Delacourte, A" uniqKey="Delacourte A" first="A" last="Delacourte">A. Delacourte</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité INSERM 156, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité INSERM 156, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1994">1994</date>
<idno type="RBID">pubmed:7858159</idno>
<idno type="pmid">7858159</idno>
<idno type="wicri:Area/PubMed/Corpus">001691</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001691</idno>
<idno type="wicri:Area/PubMed/Curation">001650</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001650</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001650</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001650</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.</title>
<author><name sortKey="Delacourte, A" sort="Delacourte, A" uniqKey="Delacourte A" first="A" last="Delacourte">A. Delacourte</name>
<affiliation wicri:level="3"><nlm:affiliation>Unité INSERM 156, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité INSERM 156, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title>
<idno type="ISSN">0753-3322</idno>
<imprint><date when="1994" type="published">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (diagnosis)</term>
<term>Alzheimer Disease (metabolism)</term>
<term>Biomarkers</term>
<term>Dementia (complications)</term>
<term>Dementia (metabolism)</term>
<term>Down Syndrome (metabolism)</term>
<term>Humans</term>
<term>Nerve Degeneration</term>
<term>Neurofibrillary Tangles (chemistry)</term>
<term>Neurofibrillary Tangles (pathology)</term>
<term>Parkinson Disease (complications)</term>
<term>tau Proteins (chemistry)</term>
<term>tau Proteins (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>tau Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>tau Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Neurofibrillary Tangles</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Alzheimer Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Alzheimer Disease</term>
<term>Dementia</term>
<term>Down Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neurofibrillary Tangles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Nerve Degeneration</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Paired Helical Filaments (PHF) accumulate in the degenerating neurons from the associative cortical brain areas during Alzheimer's disease. They are composed of a triplet of hyperphosphorylated microtubule-associated protein Tau, called Tau 55, 64, 69 or PHF-Tau. The distribution of PHF-Tau in the different brain areas corroborates neuropathological observations and specifies that: the entorhinal cortex and hippocampus are vulnerable regions specifically affected by Alzheimer-type neurofibrillary degeneration during aging, the temporal cortex is already affected at the very first stage of clinical manifestations, almost the whole brain is concerned by neurofibrillary degeneration at the end-stages of the disease. Tau-PHF are also observed in the cortical areas from Parkinson patients with dementia, and more especially in the prefrontal cortex. Tau pathology for Progressive Supranuclear Palsy is significantly different, with a doublet of pathological Tau, namely Tau 64 and 69, in almost all cortical and subcortical areas. Therefore, the presence of pathological Tau proteins in several associative cortical areas is always associated with severe intellectual impairment. Finally, PHF-Tau are powerful biochemical markers of the degenerating process which could be used for setting up an early biological diagnosis test of Alzheimer's disease based upon the immunodetection of PHF antigens in the CSF, as well as for developing experimental models of neurodegeneration.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7858159</PMID>
<DateCreated><Year>1995</Year>
<Month>03</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>1995</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0753-3322</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>7</Issue>
<PubDate><Year>1994</Year>
</PubDate>
</JournalIssue>
<Title>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</Title>
<ISOAbbreviation>Biomed. Pharmacother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.</ArticleTitle>
<Pagination><MedlinePgn>287-95</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Paired Helical Filaments (PHF) accumulate in the degenerating neurons from the associative cortical brain areas during Alzheimer's disease. They are composed of a triplet of hyperphosphorylated microtubule-associated protein Tau, called Tau 55, 64, 69 or PHF-Tau. The distribution of PHF-Tau in the different brain areas corroborates neuropathological observations and specifies that: the entorhinal cortex and hippocampus are vulnerable regions specifically affected by Alzheimer-type neurofibrillary degeneration during aging, the temporal cortex is already affected at the very first stage of clinical manifestations, almost the whole brain is concerned by neurofibrillary degeneration at the end-stages of the disease. Tau-PHF are also observed in the cortical areas from Parkinson patients with dementia, and more especially in the prefrontal cortex. Tau pathology for Progressive Supranuclear Palsy is significantly different, with a doublet of pathological Tau, namely Tau 64 and 69, in almost all cortical and subcortical areas. Therefore, the presence of pathological Tau proteins in several associative cortical areas is always associated with severe intellectual impairment. Finally, PHF-Tau are powerful biochemical markers of the degenerating process which could be used for setting up an early biological diagnosis test of Alzheimer's disease based upon the immunodetection of PHF antigens in the CSF, as well as for developing experimental models of neurodegeneration.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delacourte</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Unité INSERM 156, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Biomed Pharmacother</MedlineTA>
<NlmUniqueID>8213295</NlmUniqueID>
<ISSNLinking>0753-3322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>56</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1994</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1994</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">7858159</ArticleId>
<ArticleId IdType="pii">0753-3322(94)90174-0</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
</region>
<settlement><li>Lille</li>
</settlement>
</list>
<tree><country name="France"><region name="Hauts-de-France"><name sortKey="Delacourte, A" sort="Delacourte, A" uniqKey="Delacourte A" first="A" last="Delacourte">A. Delacourte</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001521 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001521 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:7858159
   |texte=   Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:7858159" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki